PIK3CD and acute myeloid leukemia: To do this we first assessed the effect of various PI3K inhibitors including LY294002 (pan-PI3K inhibitor, which is not suitable for clinical use as it is toxic in vivo [20]) with a concentration of 25μM [21], CAL-101 (Idelalisib - PI3Kδ inhibitor, which has been found to have a physiologically relevant concentration of between 0.3-1μM [22]) and IPI-145 (PI3Kδ and PI3Kγ inhibitor, which has a physiologically relevant concentration of 1μM [23]) on AML cell lines.